Navigation Links
Healthcare VC Dr. Dinesh Patel to serve on Tute Genomics Board of Directors
Date:11/5/2013

SALT LAKE CITY, Nov. 5, 2013 /PRNewswire-iReach/ -- Dinesh Patel, PhD, co-founder of vSpring Capital (now Signal Peak Ventures), has joined the board of directors for Utah-based Tute Genomics, founded in 2012.  Tute is a professional grade, cloud-based application for the rapid and cost-effective analysis of entire human genomes for healthcare & biomedical research. Tute Genomics comes at a time when the current pace of interpretation of genomic data cannot keep up with the increasing volume of big data that is flooding hospitals & research institutions, calling for a system to analyze these data fast enough to infer the biological insights needed to stay ahead and guide decision-making.   This is the nature of Tute's business and is aligned well with Dr. Patel's knowledge base and skill set.

(Photo:  http://photos.prnewswire.com/prnh/20131105/MN10545)

Dr. Patel brings with him decades of experience which, combined with his belief in the mission of Tute Genomics, are sure to provide a great advantage to the growing company.  Dr. Patel has had leading roles at several life sciences companies. From 1985 to 1999, Dr. Patel served as Co-Founder, Chairman of the Board of Directors and President of TheraTech, Inc., a biotechnology company which he took public and eventually sold  for $350 million to Watson Pharmaceuticals. From 1999 to 2004 he was the Founder, Chairman, and President of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected nutraceutical products. Prior to Signal Peak Ventures, Dr. Patel was an active angel investor in over 20 biotech and technology companies.

Dr. Patel also served on the board of Mediconnect Global, a worldwide leader in medical record re
'/>"/>

SOURCE Tute Genomics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
8. ViroPharma to Participate in Two December Healthcare Investor Conferences
9. Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Whitehouse Laboratories ... by the Parenteral Drug Association (PDA) to ... 2014) on container closure integrity testing. This lecture/laboratory course ... methods and philosophies detailed in the recently proposed revision ... The course will span container closure integrity testing ...
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... (Nasdaq: AMLN ) issued the following statement ... Eastbourne Capital Management, L.L.C., made public earlier today:"After significant ... unable to achieve a settlement with Eastbourne and Carl ... shareholders. Of course, we continue to remain open to ...
... ATLANTA, May 20 Germany will present itself ... locations at this year,s BIO,International Convention. Under the ... will provide invaluable insight into the,latest research results ... The,German research landscape and the regulatory framework conditions ...
... N.C., May 20 Asymchem Laboratories, Inc., a leading ... Products to the pharmaceutical industry, with sites in ... the recent addition of Dr. Chris Huber as ... the table over 15 years experience in the ...
Cached Biology Technology:Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2
(Date:9/30/2014)... The New England Journal of Medicine reports ... the drug crizotinib against the subset of lung cancer ... multi-center study of 50 patients with advanced non-small cell ... response rate was 72 percent, with 3 complete responses ... time it takes for the disease to resume its ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
... , Dec. 18, 2013 Tissue engineering ... a regenerative or reparative medicine with potential to ... engineering, which involve leveraging technologies from biomaterials, molecular ... the restructure and/or repair of human organs through ...
... have shown for the first time that the specialised role ... cilia tiny hair-like structures protruding from a cell. Stem ... body through the process of differentiation. The discovery ... therapies for a range of medical treatments where scientists aim ...
Cached Biology News:Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Lysozyme C (W-20)...
... and BR4i refrigerated multifunction centrifuges are equally capable ... a low sound level with a large range ... AUTO-LOCK rotor exchange system without tools ensures that ... seconds. Instant rotor exchange (5 sec.) ...
... X-Gal (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a ... identify recombinant plasmids. In ... and IPTG, lac ... blue, whereas recombinant colonies ...
Biology Products: